Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.…
Avalyn: Q3 Earnings Snapshot
Avalyn Pharma (NASDAQ: AVLN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 56 employees.
The shares were at 28.40 USD on 20 November 2026. Its 52-week range is 22.24 USD to 40.17 USD: the price is 29.3% below the high and 27.7% above the low.
Its market capitalisation is 1.26B USD.
Avalyn Pharma reports return on equity of 35.7% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 310.52M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 61.00 USD is 114.8% above the current price. The next earnings report is expected on 18 March 2027.